The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A member of the class of azepinoindoles that is 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one carrying additional 4-[(methylamino)methyl]phenyl and fluoro substituents at positions 2 and 8 respectively. It is an inhibitor of poly (ADP-ribose) polymerase and is used (as the camsylate salt) as monotherapy for advanced ovarian cancer and deleterious germline or somatic BRCA mutation.
[Irinotecan co-treated with rucaparib] results in increased expression of H2AX protein; [rucaparib co-treated with CPI-0610] results in increased expression of H2AX protein; [rucaparib co-treated with Dasatinib co-treated with CPI-0610] results in increased expression of H2AX protein; [rucaparib co-treated with Dasatinib] results in increased expression of H2AX protein rucaparib affects the expression of H2AX protein
[rucaparib co-treated with Dasatinib co-treated with CPI-0610] results in increased cleavage of PARP1 protein; rucaparib binds to and results in decreased activity of PARP1 protein; rucaparib inhibits the reaction [Irinotecan results in increased expression of PARP1 protein]; rucaparib promotes the reaction [navitoclax results in increased cleavage of PARP1 protein] rucaparib results in decreased expression of PARP1 protein
SRC protein affects the susceptibility to rucaparib rucaparib results in increased phosphorylation of SRC protein [rucaparib co-treated with Dasatinib] results in decreased phosphorylation of SRC protein